Should You Buy Ocugen for Its COVID Vaccine?
The coronavirus vaccine race didn't include Ocugen (NASDAQ: OCGN) a few months ago. And yet, recently, this biotech company leapt past rivals. The company is in talks with the U.S. Food and Drug Administration (FDA) regarding an Emergency Use Authorization (EUA) pathway for its candidate. All of a sudden, it looks like Ocugen is just steps away from the finish line.
As a result, Ocugen shares have soared more than 350% since the start of the year, and the company's market capitalization has grown to $1.56 billion from about $350 million in that period. So, with the possibility of a new coronavirus vaccine on the market in the U.S. -- should you buy shares of Ocugen?
Image source: Getty Images
Source Fool.com
